Publications by authors named "Chi Feng Chung"
Article Synopsis
- The phase 3 KEYNOTE-355 study showed that pembrolizumab combined with chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) in patients with untreated, advanced triple-negative breast cancer and high PD-L1 levels compared to placebo with chemotherapy.
- Approximately 64% of patients enrolled in Asian countries, such as Hong Kong, Japan, and Malaysia, had tumors with a PD-L1 combined positive score of 1 or higher, with 35% having a score of 10 or higher.
- Treatment with pembrolizumab plus chemotherapy resulted in manageable side effects, with similar rates of grade 3/4 adverse events compared to the placebo group, indicating a favorable benefit-risk profile.
Article Synopsis
- Palbociclib combined with tamoxifen was tested in a phase 3 study involving 184 women with HR+/HER2- advanced breast cancer to evaluate its efficacy and safety compared to tamoxifen alone.
- The results showed a significant improvement in progression-free survival (PFS), with a median of 24.4 months for the palbociclib-tamoxifen group versus 11.1 months for the placebo-tamoxifen group.
- While overall survival (OS) data is still being gathered, there is a trend suggesting palbociclib-tamoxifen may also reduce mortality risk, though neutropenia was a common severe side effect.
The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. Here, we report a subgroup analysis of Asian patients enrolled in DESTINY-Breast03.
View Article and Find Full Text PDFIntroduction: Appropriate malignant fungating wound (MFW) care is challenging for oncology nurses, leading to increased stress, compromised care quality, and poor patient outcomes.
Objective: This study aimed to address best practice barriers and develop evidence-based guidelines for MFW care.
Methods: This project was guided by the JBI Evidence Implementation Framework, which follows a seven-phase process.
Background: Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxane.
Methods: We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. The primary end point was progression-free survival (as determined by blinded independent central review); secondary end points included overall survival, objective response, and safety.
Background: The information of Oncotype DX applied in Asian breast cancer patients is limited. A recurrence index for distant recurrence (RI-DR) has been developed for early-stage breast cancer (EBC) from tumor samples in Chinese patients. In this study, we compared the prognostic performance of the Oncotype DX (ODx) recurrence score (RS) with the RI-DR for any recurrence risk type.
View Article and Find Full Text PDFPurpose: Breast-cancer-related lymphedema (BCRL) can be a transient or persistent condition. The aims of this study were to (1) identify and weigh the risk factors for persistent lymphedema (PLE) among all patients with BCRL and (2) establish a prediction model for the occurrence of PLE.
Methods: A cohort of 342 patients with BCRL with a median follow-up of 5 years after the onset of swelling was analyzed.